ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8178

Title: Toremifene in the treatment of breast cancer

Reviewer code: 00742507

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-12-19 15:44

Date reviewed: 2014-02-17 05:07

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[Y] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[Y] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

This review represents an excellent state-of-the-art summary of current knowledge of the effects of toremifene in treatment of breast cancer. The topic is important, the evaluation of current literature is well prepared. There is only one thing missing - the data suggest that toremifene is basically as effective as tamoxifen. Therefore, what exactly is the conclusion of this review? Are these drugs identical in effects, so it does not matter which one will be used? Or are there less side-effects with one of these? Should they be used in different groups of patients?

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8178

Title: Toremifene in the treatment of breast cancer

Reviewer code: 00398512

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-12-19 15:44

Date reviewed: 2014-03-11 15:40

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[Y] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

-correct "Letrazole" to "Letrozole" -consider avoiding "trend in favor of Toremifene" when there is no statistical difference with Tam -add a paragraph (introduction - Toremifene) commenting on the different doses of Toremifene used in studies and the current dose in the adjuvant setting. -a comment on Toremifene and bone health is missing -Discussion: add a comment on the lack of data about using Toremifene in modern hormonal treatment strategies in combination with AIs(switch, extended)